Navigation Links
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Date:12/8/2008

were
  • North America: 82.5% (85/103) for 900-mcg albinterferon alfa-2b, vs. 81.5% (88/108) for peginterferon alfa-2a;
  • Asia: 79.8% (75/94) for 900-mcg albinterferon alfa-2b, vs. 95.5% (85/89) for peginterferon alfa-2a;
  • Europe: 78.1% (64/82) for 900-mcg albinterferon alfa-2b, vs. 81.7% (67/82) for peginterferon alfa-2a;
  • Other regions: 75.8% (25/33) for 900-mcg albinterferon alfa-2b, vs. 74.2% (23/31) for peginterferon alfa-2a.
  • Patients receiving 900-mcg albinterferon alfa-2b had comparable rates of serious adverse events, severe adverse events, and discontinuations due to adverse events, vs. peginterferon alfa-2a.
  • The incidence of severe and/or serious adverse events was comparable between the two groups, with 17.3% (54/313) in the albinterferon alfa-2b 900-mcg treatment group, vs. 17.5% (54/309) in the peginterferon alfa-2a treatment group.
  • The incidence of severe and/or serious pulmonary adverse events was also comparable between these groups: severe and/or serious pulmonary infections were 0.6% (2/313) for 900-mcg albinterferon alfa-2b, vs. 0.6% (2/309) for peginterferon alfa-2a; and severe and/or serious respiratory, thoracic or mediastinal disorders were 1.0% (3/313) for 900-mcg albinterferon alfa-2b, vs. 1.3% (4/309) for peginterferon alfa-2a.
  • Overall, adverse events observed were those typically associated with interferon therapy, and the rate of discontinuations due to adverse events was comparable: 4.8% (15/313) for 900-mcg albinterferon alfa-2b, vs. 3.6% (11/309) for peginterferon alfa-2a.

    • Treatment Group Originally Randomized to Receive Albinterferon Alfa-2b 1200-mcg Every Two Weeks and Reduced to 900-mcg Following January 2008 Dose Modification, vs. Treatment Group Receiving Peginterferon Alfa-2a 180-mcg Every Week

    Due to the dose modification announced in J
    '/>"/>

    SOURCE Human Genome Sciences, Inc.
    Copyright©2008 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
    2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
    3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
    4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
    5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
    6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
    7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
    8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
    9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
    10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
    11. Premier Research Appoints Global Head of Human Resources
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
    (Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
    (Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
    (Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
    Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
    ...rrests experienced by fire fighters may be ..., Calif., Jan. 8 Masimo (Nasdaq: MASI ),the inve...and Low Perfusion,pulse oximetry, today announced ...s (IAFF) has issued education materials to more th...es and Canada calling for routine carbon,monoxide ...
    ...uary 8 Primera Biosystems,Inc., an emerging molec...fectious disease and oncology, announced today tha...ng led by Abingworth and joined by Interwest,Partn...opment Corporation,(MTDC), MPM Capital, Burrill & ...he round., "Primera plans to use this financing t...
    ...neGo, Inc., the leading,provider of databases, sof...oday that UC Berkeley will expand the use of its M...tational Toxicology course, a required,component f...onors research,programs. The agreement will provid...hway analysis tools needed to analyze complex omic...
    Other Biology Technology:International Association of Fire Fighters (IAFF) Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO-Oximetry 2International Association of Fire Fighters (IAFF) Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO-Oximetry 3International Association of Fire Fighters (IAFF) Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO-Oximetry 4International Association of Fire Fighters (IAFF) Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO-Oximetry 5Primera Biosystems Raises $21 Million in Series B Private Round 2Primera Biosystems Raises $21 Million in Series B Private Round 3UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGo's Platform 2
    (Date:12/3/2009)PHILADELPHIA Now in its 32nd year, the CTRC-AACR San Antonio Breast Cancer Symposium continues to attract the best in breast cancer science and world leaders from industry and academia with the goal
    (Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
    (Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
    Breaking Biology News(10 mins):CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Grooving down the helix 2Grooving down the helix 3Transition Therapeutics to Present at Canaccord Adams 29th Annual Global Growth Conference 53950 1Transition Therapeutics to Present at Canaccord Adams 29th Annual Global Growth Conference 53950 2Highest ever winter water temperatures recorded 9516 1Highest ever winter water temperatures recorded 9516 2NIH stimulus funding supports Emory biomedical scientists 9512 1NIH stimulus funding supports Emory biomedical scientists 9512 2NIH stimulus funding supports Emory biomedical scientists 9512 3NIH stimulus funding supports Emory biomedical scientists 9512 4
    ... San Antonio Researchers are closer to developing...n, according to a study published this week in the..., online Early Edition. Karl Klose, director of t...ases (STCEID) at The University of Texas at San An...rchers at the Burnham Institute for Medical Resear...
    ...National economies are driven by the automobile, e...ds of millions of people take their cars to visit ...arket. , The total outlay for building roads amou...-hours. Miklos Szilagyi of the University of Arizo...esources, a serious producer of pollution, congest...
    ...Researchers at the National Institute of Environme... Institutes of Health, and Duke University have di... after exposure to ozone, a common urban air pollu...also able to identify several ways to stop the air...potential new targets for drugs which may eventual...
    Other Biology News:Defectors take the car, cooperators go by bus 2Research finds new cause of ozone wheezing and potential treatments 2
    ...ection of SYBR Green I or FAM in the first channel...l including TET, HEX, VIC, and TAMRA for a multi...iscrimination. DNA Engine thermal cycler offers pr... feature permits simultaneous incubation at 12 dif...
    Fingerprinting II Identification and Library Manager from Bio-Rad
    Fingerprinting II Comparative Quantification and Polymorphism Analysis from Bio-Rad
    ... or for use in an automated line. The StatMatic II...rovides greater ease, speed, convenience, and affo...tic II can be connected to a range of bottle sizes...ded operation -- in a matter of seconds.,The Sta...
    Biology Products: